Circulating levels of neurofilament light chain as a biomarker of infarct and white matter hyperintensity volumes after ischemic stroke.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 Jul 2024
13 Jul 2024
Historique:
received:
11
01
2024
accepted:
09
07
2024
medline:
14
7
2024
pubmed:
14
7
2024
entrez:
13
7
2024
Statut:
epublish
Résumé
Serum neurofilament light chain protein (sNfL) shows promise as a biomarker for infarct size in acute ischemic stroke and for monitoring cerebral small vessel disease (cSVD). However, distinguishing the cSVD contribution after stroke may not be possible due to post-stroke sNfL increase. Additionally, it remains unclear if etiologic subtype differences exist. We measured infarct and white matter hyperintensity (WMH) volumes using MRI at the index stroke in ischemic stroke patients (n = 316, mean age 53 years, 65% males) and at 7-year follow-up (n = 187). Serum NfL concentration was measured in the acute phase (n = 235), at 3-months (n = 288), and 7-years (n = 190) post stroke. In multivariable regression, acute and 3-month sNfL concentrations were associated with infarct volume and time since stroke, but not with stroke etiology or infarct location. Seven years post-stroke, sNfL was associated with WMHs and age, but not with stroke etiology. Nonlinear regression estimated that sNfL peaks around 1 month, and declines by 50% at 3 months, and 99% at 9 months. We conclude that sNfL can indicate infarct volume and time since brain injury in the acute and subacute phases after stroke. Due to the significant post-stroke sNfL increase, several months are needed for reliable assessment of cSVD activity.
Identifiants
pubmed: 39003344
doi: 10.1038/s41598-024-67232-1
pii: 10.1038/s41598-024-67232-1
doi:
Substances chimiques
Neurofilament Proteins
0
Biomarkers
0
neurofilament protein L
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16180Subventions
Organisme : Swedish State Under the Agreement Between the Swedish Government and the County Councils (the ALF-agreement)
ID : ALFGBG- 720931
Organisme : Swedish State Under the Agreement Between the Swedish Government and the County Councils (the ALF-agreement)
ID : ALFGBG-715986
Organisme : Swedish State Under the Agreement Between the Swedish Government and the County Councils (the ALF-agreement)
ID : ALFGBG-965417
Organisme : Swedish State Under the Agreement Between the Swedish Government and the County Councils (the ALF-agreement)
ID : ALFGBG-965328
Organisme : Swedish Research Council
ID : 2022-00732
Organisme : Swedish Research Council
ID : 2018-02532
Organisme : Swedish Research Council
ID : 2021-01114
Organisme : Swedish Alzheimer Foundation
ID : AF-968270
Organisme : FP7 Ideas: European Research Council
ID : 681712
Organisme : Swedish Heart and Lung Foundation
ID : 20220184
Informations de copyright
© 2024. The Author(s).
Références
Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14(10), 577–589 (2018).
doi: 10.1038/s41582-018-0058-z
pubmed: 30171200
Gattringer, T. et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology. 89(20), 2108–2114 (2017).
doi: 10.1212/WNL.0000000000004645
pubmed: 29046363
pmcid: 5711505
Qu, Y. et al. Association of plasma neurofilament light with small vessel disease burden in nondemented elderly: A longitudinal study. Stroke. 52(3), 896–904 (2021).
doi: 10.1161/STROKEAHA.120.030302
pubmed: 33517704
Duering, M. et al. Serum neurofilament light chain levels are related to small vessel disease burden. J. Stroke 20(2), 228–238 (2018).
doi: 10.5853/jos.2017.02565
pubmed: 29886723
pmcid: 6007291
Pinter, D. et al. Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. J. Cereb. Blood Flow Metab. 39(9), 1669–1677 (2019).
doi: 10.1177/0271678X18775215
pubmed: 29737904
Tiedt, S. et al. Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke. Neurology. 91(14), e1338–e1347 (2018).
doi: 10.1212/WNL.0000000000006282
pubmed: 30217937
Walsh, P. et al. The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer’s disease. Neurobiol. Aging 97, 10–17 (2021).
doi: 10.1016/j.neurobiolaging.2020.09.008
pubmed: 33070094
Sun, Y. et al. Plasma neurofilament light and longitudinal progression of white matter hyperintensity in elderly persons without dementia. JAD 75(3), 729–737 (2020).
doi: 10.3233/JAD-200022
pubmed: 32310173
Khalil, M. et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat. Commun. 11(1), 812 (2020).
doi: 10.1038/s41467-020-14612-6
pubmed: 32041951
pmcid: 7010701
Pujol-Calderón, F. et al. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neurosci. Lett. 698, 58–63 (2019).
doi: 10.1016/j.neulet.2018.12.042
pubmed: 30599262
Onatsu, J. et al. Serum neurofilament light chain concentration correlates with infarct volume but not prognosis in acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 28(8), 2242–2249 (2019).
doi: 10.1016/j.jstrokecerebrovasdis.2019.05.008
pubmed: 31151840
Pedersen, A. et al. Circulating neurofilament light in ischemic stroke: Temporal profile and outcome prediction. J. Neurol. 266(11), 2796–2806 (2019).
doi: 10.1007/s00415-019-09477-9
pubmed: 31375988
pmcid: 6803587
Gendron, T. F. et al. Plasma neurofilament light predicts mortality in patients with stroke. Sci. Transl. Med. 12(569), eaay1913 (2020).
doi: 10.1126/scitranslmed.aay1913
pubmed: 33177179
pmcid: 9534269
Sanchez, J. D. et al. Temporal patterning of neurofilament light as a blood-based biomarker for stroke: A systematic review and meta-analysis. Front Neurol. 13, 841898 (2022).
doi: 10.3389/fneur.2022.841898
pubmed: 35651349
pmcid: 9149427
Bergman, J. et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol. Neuroimmunol. Neuroinflamm. 3(5), 1–7 (2016).
doi: 10.1212/NXI.0000000000000271
Jood, K., Ladenvall, C., Rosengren, A., Blomstrand, C. & Jern, C. Family history in ischemic stroke before 70 years of age: The Sahlgrenska Academy Study on Ischemic Stroke. Stroke. 36(7), 1383–1387 (2005).
doi: 10.1161/01.STR.0000169944.46025.09
pubmed: 15933254
Holmegaard, L. et al. Long-term progression of white matter hyperintensities in ischemic stroke. Acta Neurologica Scandinavica. 138(6), 548–556 (2018).
doi: 10.1111/ane.13019
pubmed: 30152523
Fazekas, F., Chawluk, J. B., Alavi, A., Hurtig, H. I. & Zimmerman, R. A. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am. J. Roentgenol. 149(2), 351–356 (1987).
doi: 10.2214/ajr.149.2.351
pubmed: 3496763
Gisslén, M. et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study. EBioMedicine. 3, 135–140 (2016).
doi: 10.1016/j.ebiom.2015.11.036
pubmed: 26870824
Nash, J.C. Compact Numerical Methods for Computers: Linear Algebra and Function Minimisation. 2. ed. Hilger; 1990.
Traenka, C. et al. Serum neurofilament light chain levels are associated with clinical characteristics and outcome in patients with cervical artery dissection. Cerebrovasc. Dis. 40(5–6), 222–227 (2015).
doi: 10.1159/000440774
pubmed: 26418549
Chen, Y. J. et al. Wallerian degeneration beyond the corticospinal tracts: Conventional and advanced MRI findings: Wallerian degeneration: Conventional & advanced MRI findings. J. Neuroimaging. 27(3), 272–280 (2017).
doi: 10.1111/jon.12404
pubmed: 28072502
Friede, R. L. & Samorajski, T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat. Rec. 167(4), 379–387 (1970).
doi: 10.1002/ar.1091670402
pubmed: 5454590
Buss, A. Gradual loss of myelin and formation of an astrocytic scar during Wallerian degeneration in the human spinal cord. Brain 127(1), 34–44 (2004).
doi: 10.1093/brain/awh001
pubmed: 14534158
Thomalla, G. et al. Diffusion tensor imaging detects early Wallerian degeneration of the pyramidal tract after ischemic stroke. NeuroImage. 22(4), 1767–1774 (2004).
doi: 10.1016/j.neuroimage.2004.03.041
pubmed: 15275932
Kern, D. et al. Serum NfL in Alzheimer dementia: Results of the Prospective Dementia Registry Austria. Medicina. 58(3), 433 (2022).
doi: 10.3390/medicina58030433
pubmed: 35334608
pmcid: 8955532
Hu, X., Yang, Y. & Gong, D. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: A meta-analysis. Neurol. Sci. 38(3), 407–414 (2017).
doi: 10.1007/s10072-016-2783-7
pubmed: 27896490
Wilke, C. et al. Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: A pilot study. J. Neurol. 265(7), 1618–1624 (2018).
doi: 10.1007/s00415-018-8893-9
pubmed: 29737427
Martín-Aguilar, L. et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. J. Neurol. Neurosurg. Psychiatry 92(1), 70–77 (2021).
doi: 10.1136/jnnp-2020-323899
Gouw, A. A. et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: The Leukoaraiosis and Disability study. Stroke. 39(5), 1414–1420 (2008).
doi: 10.1161/STROKEAHA.107.498535
pubmed: 18323505
Schmidt, R., Enzinger, C., Ropele, S., Schmidt, H. & Fazekas, F. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet. 361(9374), 2046–2048 (2003).
doi: 10.1016/S0140-6736(03)13616-1
pubmed: 12814718
Koini, M. et al. Factors influencing serum neurofilament light chain levels in normal aging. Aging. 13(24), 25729–25738 (2021).
doi: 10.18632/aging.203790
pubmed: 34923481
pmcid: 8751593
Kaeser, S. A. et al. A neuronal blood marker is associated with mortality in old age. Nat. Aging. 1(2), 218–225 (2021).
doi: 10.1038/s43587-021-00028-4
pubmed: 37118632
Barrett, K. M., Ding, Y. H., Wagner, D. P., Kallmes, D. F. & Johnston, K. C. Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: Results of the acute stroke accurate prediction (ASAP) trial serial imaging substudy. Stroke. 40(7), 2422–2427 (2009).
doi: 10.1161/STROKEAHA.109.548933
pubmed: 19443798
pmcid: 2772139
Fainardi, E. et al. T
doi: 10.1002/ana.26354
pubmed: 35285078
pmcid: 9322332
Kuhle, J. et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab Med. 54(10), 1655–1661 (2016).
doi: 10.1515/cclm-2015-1195
pubmed: 27071153
Keshavan, A., Heslegrave, A., Zetterberg, H. & Schott, J. M. Stability of blood-based biomarkers of Alzheimer’s disease over multiple freeze-thaw cycles. Alzheimers Dement. 10(1), 448–451 (2018).